Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna ...

Morgan Stanley slashed its price target on Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to $38 from $70 given the lowered revenue guidance and ongoing competitive pressures in the vaccine market.

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

No scientific studies have established a causal relationship between the Pfizer vaccine and conditions that cause the excessive growth of breasts.

A number of drug companies are working to develop a vaccine, led by Moderna Inc., which won a $176 million award from the Biomedical Advanced Research and Development Authority to develop its ...

Beyond sidestepping people’s fear of needles, these vaccines would also make it easier to store and distribute ahead of ...

BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...

The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...

Stock-plunging mRNA vaccine maker, already in bed with feds on vaccine royalties, says booster not "causally" related without ...

There is a distrust of, and dislike of mRNA vaccines among some people. Though the risk of death from Covid still exceeds ...